Table 1.

Total Antimicrobial Use (AU) and Selected Antibiotic (Ab) and Antifungal (Af) Use in February, March, and April 2019 and 2020, in Days of Therapy (DOT) per 100 Days Present (DP) in PICU and Non-PICU Areas (Excluding Operating Rooms)^a

		February (DOT/100 DP)			March (DOT/100 DP)			April (DOT/100 DP)
	Year	Non-PICU	PICU	Total	Non-PICU	PICU	Total	Non-PICU	PICU	Total
AU (Ab+Af)	2019	62.9	109.2	172.1	63.3	91.9	155.2	63.3	82.8	146.0
	2020	−0.4	−10.0	−10.4	+6.6	+6.6	+13.2	−1.4	+56.9	+55.5
Total Antibiotics	2019	57.4	103.5	160.9	57.4	89.6	147.0	57.2	79.5	136.7
	2020	−0.8	−9.9	−10.7	+4.5	−2.9	+1.6	−2.0	+37.5	+35.5
Total Antifungals	2019	5.5	5.7	11.2	5.9	2.3	8.2	6.1	3.2	9.3
	2020	+0.5	−0.2	+0.3	+2.1	+9.5	+11.6	+0.6	+19.4	+19.9
Selected Antibiotics
Amikacin	2019	1.1	6.1	7.2	0.4	1.5	1.9	0.7	0.5	1.2
	2020	−0.3	−4.6	−4.9	+0.8	−0.7	+0.1	+0.2	+0.8	+1.0
Amoxicillin	2019	3.8	2.6	6.4	3.4	4.6	8.0	4.3	0.5	4.8
	2020	+0.7	−1.0	−0.3	+0.6	−1.1	−0.5	−2.1	+5.3	+3.2
Amoxicillin/clavulanate	2019	11.2	12.9	24.0	12.7	9.6	22.3	12.7	8.5	21.2
	2020	−0.9	+0.4	−0.6	−2.0	−2.1	−4.1	−5.4	−2.3	−7.7
Ampicillin	2019	5.2	1.3	6.5	4.2	5.1	9.3	3.6	1.4	5.0
	2020	−1.9	+0.8	−1.1	−0.7	−2.6	−3.3	−1.4	+0.2	−1.2
Azithromycin	2019	1.5	3.3	4.8	2.1	4.8	6.9	2.2	6.0	8.1
	2020	+0.2	+1.2	+1.4	+0.9	+4.2	+5.1	+0.4	+4.1	+4.5
Cefazolin	2019	1.4	17.9	19.2	1.9	15.8	17.8	2.1	15.7	17.8
	2020	+1.4	−4.4	−3.0	+0.3	−2.5	−2.2	−1.1	−2.5	−3.6
Cefotaxime	2019	2.3	12.4	14.7	2.8	6.8	9.6	1.3	9.7	11.0
	2020	−0.8	−4.1	−4.9	−1.0	−2.4	−3.4	+0.6	−3.5	−2.9
Ceftazidime	2019	0.7	5.0	5.7	0.6	0.8	1.4	0.2	0.9	1.1
	2020	+0.1	−4.7	−4.7	+0.2	0	+0.2	+0.3	−0.9	−0.6
Ceftriaxone	2019	5.2	1.7	7.0	5.4	2.6	8.1	5.8	1.4	7.1
	2020	−1.3	+1.7	+0.4	0	+0.2	+0.2	+0.1	+1.8	+1.8
Ciprofloxacin	2019	1.2	3.1	4.2	1.3	4.5	5.7	1.5	6.8	8.3
	2020	+0.2	+1.7	+1.9	+0.6	−2.0	−1.4	+1.3	+0.3	+1.7
Linezolid	2019	0.1	3.1	3.1	0.2	2.3	2.5	0.3	1.0	1.3
	2020	+0.3	+0.7	+1.0	−0.1	−2.1	−2.3	−0.2	−0.1	−0.4
Meropenem	2019	5.0	3.7	8.7	4.0	2.8	6.8	5.1	4.6	9.7
	2020	−2.2	−1.2	−3.4	−0.9	+0.9	−0.1	−1.9	+4.8	+2.9
Piperacillin/tazobactam	2019	2.3	6.8	9.0	1.2	10.7	12.0	1.9	4.9	6.9
	2020	+1.4	+0.7	+2.0	+3.2	+2.9	+6.2	+2.6	+12.3	+14.9
Teicoplanin	2019	0.1	0.4	0.5	0.2	1.0	1.2	0.2	1.2	1.4
	2020	+0.7	+0.6	+1.3	+0.7	+2.0	2.7	+0.2	+7.1	+7.3
Vancomycin	2019	3.8	15.0	18.8	3.1	10.9	14.0	3.3	7.2	10.5
	2020	+0.3	−2.0	−1.7	+2.4	−1.4	+1.0	+0.7	+0.9	+1.5
Selected Antifungals
Fluconazole	2019	1.6	0.7	2.2	0	2.3	2.3	2.6	3.2	5.8
	2020	+1.9	−0.4	+1.5	+2.7	−1.6	+1.1	−2.4	−3.2	−5.7
Liposomal amphotericin	2019	1.6	0.4	2.0	1.7	0	1.7	1.5	0	1.5
	2020	−0.7	+1.0	+0.4	+1.5	+1.0	+2.5	+1.8	+1.6	+3.4
Micafungin	2019	0.6	3.9	4.6	0	0	0	0	0	0
	2020	+0.1	−0.7	−0.6	+0.1	+7.0	+7.1	+0.3	+13.2	+13.5
Posaconazole	2019	1.0	0	1.0	0.3	0	0.3	1.2	0	1.2
	2020	−0.5	+0.4	0	+1.2	+0.3	+1.5	+1.0	+0.7	+1.6
Voriconazole	2019	0.7	0.7	1.4	1.4	0	1.4	0.4	0	0.4
	2020	−0.3	−0.7	−1.0	−1.0	+2.8	+1.8	+0.2	+7.2	+7.3

Note. Ab, antibiotic; Af, antifungal; AU, antimicrobial use; DOT, days of therapy; DP, days present; PICU, pediatric intensive care unit.

^a Year 2020 data are given as increases or decreases compared to the same month in year 2019.